Subtypes of irritable bowel syndrome in children and adolescents
- PMID: 24486406
- PMCID: PMC4428553
- DOI: 10.1016/j.cgh.2014.01.031
Subtypes of irritable bowel syndrome in children and adolescents
Abstract
Background & aims: Pharmacologic treatments for irritable bowel syndrome (IBS) and medical management of symptoms are increasingly based on IBS subtype, so it is important to accurately differentiate patients. Few studies have classified subtypes of pediatric IBS, and conclusions have been challenged by methodologic limitations. We performed a prospective study to investigate the distribution of IBS subtypes among children and adolescents based on stool diary information, and compared subtypes according to demographic and pain characteristics.
Methods: We studied 129 subjects, ages 7 to 18 years (mean age, 11.4 ± 2.8 y; 60.5% female; 69.0% white) who met Pediatric Rome III IBS criteria and were part of larger studies of children with functional gastrointestinal disorders, recruited from primary and tertiary care centers. Children completed daily pain and stool diaries for 2 weeks. Participants were assigned IBS subtypes based on their reported stool information per adult Rome III criteria. IBS subtypes were compared for demographic variables and pain characteristics.
Results: IBS with constipation was the most common subtype of the disorder (58.1% of subjects), whereas mixed IBS was the least common (2.3% of subjects); 34.1% of subjects were unsubtyped IBS and 5.4% had IBS with diarrhea. The groups of different IBS subtypes did not differ significantly by sex, age, ethnicity, or pain characteristics.
Conclusions: In contrast to adults, in children, IBS with constipation and unsubtyped IBS are the most common subtypes, whereas IBS with diarrhea and mixed IBS are less common. Demographic and pain characteristics cannot distinguish subtypes.
Keywords: Children; IBS Subtypes; Irritable Bowel Syndrome; Pediatric Functional GI Disorders.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar.J Clin Gastroenterol. 2009 Mar;43(3):214-20. doi: 10.1097/MCG.0b013e31815bd749. J Clin Gastroenterol. 2009. PMID: 19623100
-
Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.Am J Gastroenterol. 2021 Feb 1;116(2):362-371. doi: 10.14309/ajg.0000000000000946. Am J Gastroenterol. 2021. PMID: 33009062
-
Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study.J Gastroenterol Hepatol. 2012 Apr;27(4):760-5. doi: 10.1111/j.1440-1746.2011.06930.x. J Gastroenterol Hepatol. 2012. PMID: 21929652
-
Irritable Bowel Syndrome: Straightening the road from the Rome criteria.Neurogastroenterol Motil. 2020 Nov;32(11):e13957. doi: 10.1111/nmo.13957. Epub 2020 Aug 17. Neurogastroenterol Motil. 2020. PMID: 32808411 Free PMC article. Review.
-
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Lancet Gastroenterol Hepatol. 2020. PMID: 32702295
Cited by
-
Differential Effects of Sucrase-Isomaltase Mutants on Its Trafficking and Function in Irritable Bowel Syndrome: Similarities to Congenital Sucrase-Isomaltase Deficiency.Nutrients. 2020 Dec 22;13(1):9. doi: 10.3390/nu13010009. Nutrients. 2020. PMID: 33375084 Free PMC article.
-
Childhood Irritable Bowel Syndrome Characteristics Are Related to Both Sex and Pubertal Development.J Pediatr. 2017 Jan;180:141-147.e1. doi: 10.1016/j.jpeds.2016.08.045. Epub 2016 Sep 14. J Pediatr. 2017. PMID: 27639531 Free PMC article.
-
'Rapid transit' constipation in children: a possible genesis for irritable bowel syndrome.Pediatr Surg Int. 2020 Jan;36(1):11-19. doi: 10.1007/s00383-019-04587-x. Epub 2019 Oct 31. Pediatr Surg Int. 2020. PMID: 31673760 Review.
-
Prevalence of irritable bowel syndrome and its association to mental health among the private university students of Dhaka, Bangladesh.PLOS Glob Public Health. 2025 May 22;5(5):e0004670. doi: 10.1371/journal.pgph.0004670. eCollection 2025. PLOS Glob Public Health. 2025. PMID: 40402939 Free PMC article.
-
Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders.Qual Life Res. 2017 Apr;26(4):1015-1025. doi: 10.1007/s11136-016-1430-3. Epub 2016 Oct 14. Qual Life Res. 2017. PMID: 27743332
References
-
- Longstreth GF, Thompson WG, Chey WE, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91. - PubMed
-
- Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035–40. - PubMed
-
- Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161:1733–40. - PubMed
-
- Chey WD. Review article: Tegaserod – the globall experience. Aliment Pharmacol Ther. 2004;20(Suppl. 7):15–9. - PubMed
-
- Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655–66. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous